Suspension: 40 mg/ml
Refractory invasive fungal infections:
Second line if intolerant or resistant to standard therapy
200 mg four times a day with food supplement or 400 mg twice a day
200 mg as an initial dose on day 1 followed by 100 mg for 13 days
Neutropenia, electrolyte imbalance, anorexia, paresthesia, dizziness, somnolence, headache, QTc/QT prolongation, abnormal ECG, palpitation, vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, dry mouth, flatulence, elevated liver function tests (including ALT, AST, bilirubin, alkaline phosphatase, GGT) rash, pyrexia (fever), asthenia, fatigue
Posaconazole is metabolized via UDP glucuronidation, and is a substrate for p-glycoprotein as well as an inhibitor of CYP3A4
Posaconazole AUC is decreased 50% by rifabutin and phenytoin, and 40% by cimetidine
Posaconazole increases AUC of rifabutin by 72%: avoid combination, or maintain vigilance for uveitis
Posaconazole is expected to increase exposure of HIV PIs and NNRTIs, tacrolimus, ciclosporin, midazolam, digoxin, calcium antagonists, HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin). Seek specialist HIV pharmacist advice.Administration with terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine may increase risk of QT prolongation, and is contraindicated.
No dose adjustment required
Limited data in hepatic impairment and no recommendation can be made
No Human Data – Animal Data Suggest Risk.